For example, Ha et al. previously showed that only 1 in 3 patients with inflammatory bowel disease (IBD) in routine clinical practice would have qualified for the pivotal trials evaluating the efficacy and safety of TNF antagonists,9 and similar findings have been shown in RCTs of other chronic inflammatory diseases.10,11. This evidence concerns the gene TNF and inflammatory bowel disease.